RALLYBIO CORP(NASDAQ:RLYB) stock News

RLYB Latest News, Press Relases and Analysis

All

Press Releases

16 hours ago - By: Benzinga - Mentions: SNGX ANTX CHEK ADAP ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

21 days ago - By: Rallybio Corporation

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

a month ago - By: Yahoo Finance - Mentions: RXRX

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

3 months ago - By: The Motley Fool - Mentions: RXRX

Here's Why Shares in Recursion Pharmaceuticals Surged Today

2 months ago - By: Rallybio Corporation

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Benzinga - Mentions: ANGO MDXG TLPH ATLN ...

12 Health Care Stocks Moving In Monday's After-Market Session

3 months ago - By: Yahoo Finance - Mentions: RXRX UBS GMAB

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

3 months ago - By: Yahoo Finance - Mentions: RXRX

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

3 months ago - By: Yahoo Finance - Mentions: RXRX

Here's Why Shares in Recursion Pharmaceuticals Surged Today

3 months ago - By: Rallybio Corporation

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

3 months ago - By: Rallybio Corporation

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

5 months ago - By: Rallybio Corporation

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

5 months ago - By: Rallybio Corporation

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

6 months ago - By: Yahoo Finance - Mentions: CALM

Trade policy changes alone won’t bring manufacturing back

6 months ago - By: Rallybio Corporation

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

7 months ago - By: Rallybio Corporation

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

7 months ago - By: Rallybio Corporation

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

8 months ago - By: Rallybio Corporation

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

9 months ago - By: Rallybio Corporation

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

10 months ago - By: Rallybio Corporation

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

10 months ago - By: Rallybio Corporation

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

10 months ago - By: Rallybio Corporation

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

10 months ago - By: Rallybio Corporation

RALLYBIO CORP (RLYB) Stock News

RLYB Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

12 Health Care Stocks Moving In Monday's After-Market Session

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Trade policy changes alone won’t bring manufacturing back

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference